Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com

StockNews.com lowered shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a report published on Monday.

A number of other equities analysts have also recently commented on ATNM. HC Wainwright cut their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, Maxim Group lowered their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.40.

Actinium Pharmaceuticals Price Performance

ATNM opened at $1.71 on Monday. Actinium Pharmaceuticals has a one year low of $1.33 and a one year high of $10.24. The firm has a market capitalization of $53.35 million, a PE ratio of -1.13 and a beta of 0.14. The business’s 50-day moving average price is $1.80.

Institutional Trading of Actinium Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Marshall Wace LLP grew its position in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after purchasing an additional 103,557 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Actinium Pharmaceuticals during the 3rd quarter worth approximately $322,000. Bank of New York Mellon Corp raised its position in shares of Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after buying an additional 62,459 shares in the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).